Pfizer CEO Albert Bourla said an oral drug for the treatment of the coronavirus could be ready next year, adding that the company is working on two antivirals, one oral and one injectable.
“In reality we are two, one is injectable and the other an oral (antiviral) … In particular, the focus is on oral for the world and for us because it offers several advantages and one of these is that you don’t need to go to the hospital to get the treatment that’s the case with all the injectables so far, but you can take it home, “Albert Bourla told CNBC on Tuesday in an interview, as quoted by The Hill.
“If all goes well, and we implement the same speed as we are, and if the regulators do the same, and they are, I hope by the end of the year,” added Albert Bourla.
The only antiviral currently approved for use against coronavirus is remdesivir, manufactured by Gilead Sciences. The U.S. Food and Drug Administration (FDA) gave the drug full approval in October, after it was granted emergency use authorization in May last year.
He also said the drug could be “much more effective against multiple variants” of the virus than current options, adding that the antiviral’s mechanism of action should not be prone to mutations, “particularly because it does not act on the spike. as we all know, all the mutations we are feeling right now are seeing it in the spike proteins. “
“This doesn’t work there, so it allows us to believe it will be much more effective against multiple variants. So, all good news. We are now advancing the studies and will have more news around the summer,” added the CEO.
The Hill also reported that more than 121 million doses of the vaccine have been administered in the United States so far.